Delisting risk
BRNS · NASDAQ · Biotechnology

Barinthus Biotherapeutics (ADR) (BRNS)

Develops immune-tolerance therapies for celiac disease while seeking partners for legacy viral-vector programs.

$0.7600
Pre-market−0.01 (−1.92%)
At close$0.7749(+1.29%)

Something off on this page? Send us feedback.

Next report
Nov 6, 2026
estimated · in 64 days
EPS estimate
−$0.27
Revenue estimate
$216.9K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26Apr '26Aug '26Nov '26
Reported−$0.51−$0.49−$0.52−$0.36−$0.27−$0.14−$0.26Pending
Estimate−$0.50−$0.34−$0.29−$0.45−$0.40−$0.36−$0.28−$0.27
Surprise−2.0%−44.1%−79.3%+20.0%+32.5%+61.1%+7.1%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26Apr '26Aug '26Nov '26
Reported−$9.2MPending
Estimate$216.9K
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.27
Aug 2026−$0.28−$0.26+7.1%
Apr 2026−$0.36−$0.14+61.1%
Mar 2026−$0.40−$0.27+32.5%
Nov 2025−$0.45−$0.36+20.0%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 6, 2026−$0.27$216.9K
Aug 6, 2026−$0.28−$0.26+7.1%−0.9%
Apr 30, 2026−$0.36−$0.14+61.1%+0.1%
Mar 13, 2026−$0.40−$0.27+32.5%+8.1%
Nov 7, 2025−$0.45−$0.36+20.0%−17.8%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 7, 2025
May 7, 2025
Mar 20, 2025
Nov 6, 2024
Aug 8, 2024
May 13, 2024
Mar 20, 2024
Nov 9, 2023
Aug 10, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020